Sarepta Therapeutics (SRPT) Leases (2013 - 2026)

Sarepta Therapeutics has reported Leases for 9 years, with the latest figure at $124.1 million in Q1 2026.

• For the quarter ending Q1 2026, Leases fell 15.64% year-over-year to $124.1 million; the trailing twelve-month figure through Mar 2026 stood at $124.1 million (down 15.64% YoY), and the FY2025 full-year result was $125.5 million, down 15.38% from the prior year.
• Leases for Q1 2026 stood at $124.1 million, down from $125.5 million in the prior quarter.
• The five-year high for Leases was $148.3 million in Q4 2024, with the low at $43.0 million in Q3 2022.
• Average Leases over 5 years is $110.6 million, with a median of $126.3 million recorded in 2024.
• Year-over-year, Leases tumbled 40.78% in 2022 and jumped 210.11% in 2023.
• Tracing SRPT's Leases over 5 years: stood at $65.0 million in 2022, then jumped by 100.07% to $130.0 million in 2023, then climbed by 14.13% to $148.3 million in 2024, then declined by 15.38% to $125.5 million in 2025, then declined by 1.14% to $124.1 million in 2026.
• The last three Leases figures came in at $124.1 million (Q1 2026), $125.5 million (Q4 2025), and $139.2 million (Q3 2025), per Business Quant data.

Peer Comparison